April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
The Effect of Tapered Small Dose Steroidal Treatment on Symptoms, Clinical Signs, and Ocular Surface Inflammation in Patients with Dry Eye Syndrome
Author Affiliations & Notes
  • Stefano Barabino
    Clinica Oculistica,
    University of Genoa, Genoa, Italy
  • Elisa Montaldo
    Experimental Medicine,
    University of Genoa, Genoa, Italy
    IST, Genoa, Italy
  • Elisabetta Corsi
    Clinica Oculistica,
    University of Genoa, Genoa, Italy
  • Cristiana Valente
    Clinica Oculistica,
    University of Genoa, Genoa, Italy
  • Federico Solignani
    Clinica Oculistica,
    University of Genoa, Genoa, Italy
  • Maria Cristina Mingari
    Experimental Medicine,
    University of Genoa, Genoa, Italy
    IST, Genoa, Italy
  • Maurizio Rolando
    Clinica Oculistica,
    University of Genoa, Genoa, Italy
  • Footnotes
    Commercial Relationships  Stefano Barabino, None; Elisa Montaldo, None; Elisabetta Corsi, None; Cristiana Valente, None; Federico Solignani, None; Maria Cristina Mingari, None; Maurizio Rolando, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 3826. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Stefano Barabino, Elisa Montaldo, Elisabetta Corsi, Cristiana Valente, Federico Solignani, Maria Cristina Mingari, Maurizio Rolando; The Effect of Tapered Small Dose Steroidal Treatment on Symptoms, Clinical Signs, and Ocular Surface Inflammation in Patients with Dry Eye Syndrome. Invest. Ophthalmol. Vis. Sci. 2011;52(14):3826.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine whether treatment with small tapered doses of steroid (loteprednolol etabonate) can reduce symptoms, signs and conjunctival epithelium expression of inflammatory markers in patients with dry eye syndrome (DES).

Methods: : Twenty patients with DES have been enrolled for this double-masked, randomized, pilot study. Diagnosis of DES and treatment outcomes were assessed by means of OSDI questionnaire, Schirmer I test, tear break-up time (BUT), lissamine green conjunctival staining (NEI scoring system), fluorescein corneal staining, and HLA-DR expression on conjunctival cells. The enrolled patients were divided into 2 groups: study group (n=10) was treated with loteprednolol etabonate 0.5% b.i.d. for 14 days tapered at once a day for 15 days, and then every other day for 4 weeks. Control group underwent the same regimen with NaCl 0.9%. Best corrected visual acuity, intraocular pressure and evaluations were performed at day 0, day 14, and day 56.

Results: : A significant decrease of ocular surface inflammation and improvement of symptoms was recorded in the study group compared to controls at day 14 and 56. No significant difference was found for BUT and corneal fluorescein staining, but there was a consistent trend for improvement of lissamine green staining in the study group. None of the treated eyes showed significant increase in intraocular pressure or worsening of best corrected visual acuity.

Conclusions: : Treatment with tapered doses of loteprednol etabonate 0.5% suspension seems to control ocular surface inflammation and damage, improving dry eye patient’s symptoms. Larger studies are necessary to confirm these preliminary results.

Clinical Trial: : http://www.trialregister.nl/trialreg/index.asp 2291

Keywords: cornea: tears/tear film/dry eye • inflammation • cornea: epithelium 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×